NovaBridge Biosciences American Depositary Shares (NBP) is a publicly traded the market company. As of May 21, 2026, NBP trades at $1.72 with a market cap of $197.76M and a P/E ratio of 0.00. NBP moved +5.36% today. Year to date, NBP is -59.73%; over the trailing twelve months it is flat. Its 52-week range spans $1.67 to $5.19. Analyst consensus is buy with an average price target of $9.00. Rallies surfaces NBP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
NovaBridge Hires Mark Hagler to Drive Commercialization of Givastomig and VIS-101: NovaBridge appointed Mark Hagler as President and Chief Commercial Officer to lead commercial strategy and maximize value of its givastomig and VIS-101 pipelines. Hagler brings over 25 years of biopharma leadership, including launching Abraxane and Afinitor, to shape clinical trial design and drive pre-commercial readiness.
| Metric | Value |
|---|---|
| Price | $1.72 |
| Market Cap | $197.76M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $5.19 |
| 52-Week Low | $1.67 |
| Volume | 21.86K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $0 |
| Gross Margin | 0.00% |
1 analysts cover NBP: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $9.00.